Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2018-10-18 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于公司会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding changes in accounting policies. It details the nature of the accounting policy changes, their impact, and includes opinions from the board of directors, independent directors, and the supervisory board. The document is relatively short (2020 characters) and does not contain actual financial statements or detailed financial data. Instead, it serves as a formal announcement about the accounting policy change and related approvals. Therefore, it is not an Annual Report (10-K), Interim Report (IR), or Audit Report (AR), but rather a regulatory announcement about accounting policy changes. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-10-18 Chinese
八届五十七次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details the decisions made at the 57th meeting of the 8th board, including approval of a change in accounting policy and approval of the 2018 third quarter report. The document is short (534 characters) and primarily announces the board's resolutions rather than providing the full report or detailed financial data. It is not the actual quarterly report but an announcement of board decisions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board.
2018-10-18 Chinese
八届二十九次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the supervisory board of Kunming Pharmaceutical Corporation regarding the resolution of the 29th meeting of the 8th Supervisory Board. It discusses the election and nomination of candidates for the 9th Supervisory Board, including voting results and procedural details. The document is an official announcement of board/management changes and related resolutions, not a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a report publication announcement. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on governance changes, confirming this classification.
2018-10-17 Chinese
关于董事会、监事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election and nomination of the company's board of directors and supervisory board members. It details the candidates for the new board and supervisory board, their qualifications, and the procedural steps for the election. There is no financial data, no discussion of financial results, no audit information, no legal proceedings, no capital changes, and no voting results. The content is focused on changes in the company's board and senior management structure. Therefore, this document fits the category of Board/Management Information (MANG). The document length is sufficient and the content is substantive, not just a brief announcement or a report publication notice.
2018-10-17 Chinese
独立董事关于公司董事会换届选举事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the board of directors' re-election matters. It references compliance with relevant laws and regulations, qualifications of director candidates, and nomination procedures. It concludes with agreement on the nomination of candidates for the board and submission of related proposals to the 2018 fifth extraordinary shareholders' meeting. The content focuses on board/management information, specifically about director nominations and board changes. The document length is short and it is not a full report but a formal opinion related to board changes. Therefore, the appropriate classification is Board/Management Information (MANG).
2018-10-17 Chinese
独立董事关于公司以集中竞价交易方式回购公司股份的独立意见
Transaction in Own Shares Classification · 95% confidence The document is an independent opinion statement from the independent directors of Kunming Pharmaceutical Group Co., Ltd. regarding the company's share repurchase plan through centralized bidding. It references relevant regulatory guidelines and confirms the legality, necessity, and feasibility of the share buyback plan. The document does not contain financial statements or detailed financial data but is a formal opinion related to a share repurchase transaction. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2018-10-17 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.